KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes.

Rushabh Kothari, Vijay Patil, Ravi Krishna Madala, Ravikant Singh, Vikas T Talreja, Anand Pathak, Sameer Shrirangwar, Tanmoy Kumar Mandal, Sudeep Das, Siddharth Turkar, Nikhil Pande, Arun Chandrasekharan, Gunjesh Singh, Tara Chand Gupta, Bhavesh Poladia, Manuprasad Avaronnan, Lovin Wilson, Nirmal Raut, Monica Jadhav, Mitali Alone, Manali Kolkur, Priyanka Bhagyavant, Shruti Pathak, Zoya Peelay, Gaurang Modi, Itesh Khatwani, Palak Bhatt, Gautam Kumar, Bhavya Jha, Unnati Singh, Kamlesh Madankar, Nibedita Sen, Vaibhav Sonwani, Sonal Muley, Sajith Babu Thavarool, Bharat Bhosale, Rakesh Katna, Deepan Rajamanickam, Saravana Rajamanickam, Praveen Kumar Shenoy Vp, Ashay Karpe, S D Banavali, Vanita Noronha, Kumar Prabhash

Cancer Lett 621 217702

PMID40209850
PMCID-
DOI10.1016/j.canlet.2025.217702
发表日期2025-04-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

There are multiple options of treatment in second line therapy for locally advanced head and neck squamous cell carcinoma (LAHNSCC) treated with palliative intent. However, triple metronomic chemotherapy is oral, cost-effective, and resource-efficient. Hence this phase 3 randomized trial compares National Comprehensive Cancer Network (NCCN) recommended physician choice therapy versus triple metronomic chemotherapy (TMC) in the second-line treatment of head and neck cancer This study, designed to establish superiority, was conducted in India across 16 sites under the Cancer Research Statistics Foundation. The study recruited 114 LAHNSCC who were treated with palliative intent in second line. These patients underwent 1:1 central stratified randomization to either triple metronomic chemotherapy or physician choice therapy (taxane, 5fu/capecitabine, afatinib, nivolumab/pembrolizumab, cetuximab).At a median follow-up of 258 (95 % CI 209-306) days, the median overall survival of the triple metronomic chemotherapy was 181 days (95 %CI 142.7-219.2) versus 123 days (95 %CI 94-152) in the physician choice therapy arm (P = 0.00.002). The median progression free survival was 120 days (95 %CI 89.2-150.8) versus 70 days (95 % CI 58.2-81.8) in metronomic chemotherapy and in the physician choice therapy arms respectively (P < 0.001).These results suggest that TMC significantly improves survival outcomes over physician choice therapy in platinum-refractory head and neck cancer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。